Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    Mechanism of Action for Drugs Against Arenaviruses

    By Global Biodefense StaffJuly 21, 2014
    USAMRIID Arenavirus Mechanism of Action
    Share
    Facebook LinkedIn Reddit Email

    The U.S. Army Medical Research Acquisition Activity (USAMRAA) is seeking firms capable of providing research services to develop mechanisms of action for FDA-approved drugs against Arenaviruses.

    The contract will support ongoing work on biothreat countermeasures by the Virology Division within the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

    USAMRIID has screened a library containing over 3200 FDA-approved drugs to identify ones that inhibit infections by multiple pathogenic viruses. Those tested include six hemorrhagic fever viruses (Ebolavirus, Marburgvirus, Dengue Virus, West Nile Virus, Lassa Fever Virus, and Rift Valley Fever Virus) and four alphaviruses (Western, Eastern, and Venezuelan encephalitis viruses and Chikungunya virus), representing 5 families of enveloped RNA viruses (filo-, flavi-, arena-, bunya-, and alphaviruses).

    From this effort, they have identified approximately 140 Highly Active Anti-viral Lead Therapeutics (HALLT) compounds that block infection by members of two or more virus families. Understanding the Mechanism of Action (MOA) would improve understanding as to how these compounds may be inhibiting infection and at which stage of virus replication to develop more effective therapeutics.

    Previous efforts against filoviruses have focused on specifically designed Ebolavirus (EBOV) virus like particles (VLPs) that recapitulate the filamentous shape and entry properties of authentic EBOV, through the incorporation of the EBOV glycoprotein (GP). Just like other enveloped viruses, it is the GP that dictates all aspects of virus entry. Additionally, these VLPs incorporate two engineered forms of EBOV VP40, one tagged with β-lactamase and one tagged with mCherry. VP40 directs the assembly of EBOV VLPs, similar to authentic virus. The β-lactamase VP40 acts a reported when the VLPs have fused with a cellular membrane and have entered into the cytoplasma; whereas, the mCherry VP40 provides a fluorescent tag for visualizing the VLPs during cellular entry.

    The proposed work for this solicitation is to develop a similar pseudoviron assay for arenaviruses and identify the mechanism of action of several compounds identified in the authentic virus screens completed by USAMRIID.

    USAMRAA anticipates awarding a single contract for one base year plus four option years for these services.

    Further details are available under Solicitation Number: W81XWH-14-R-0082. The response deadline is July 31, 2014.

    Arenavirus Ebola Lassa Fever RFI
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleDARPA BAA for Pathogen Predators
    Next Article Potential New Flu Drugs Target Immune Response, Not Virus

    Related Stories

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    NIAID Seeks to Improve Computational Models of Influenza Immunity

    September 15, 2023

    Case Study: Fatal Avian Influenza Infection in Cat in Poland

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy